SCHEMBL9902373

SCHEMBL9902373

CC(C)(C)OC(=O)N1CCOc2c(-c3ccoc3)csc2C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 2/20 0.43
USP2 O75604 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ESR2 Q92731 1/20 0.35
ADORA1 P30542 1/20 0.35
KDM4E B2RXH2 1/20 0.35
MAPT P10636 1/20 0.35
SCD5 Q86SK9 1/20 0.35
NR1H2 P55055 2/20 0.34
MAPK1 P28482 1/20 0.34
RIPK1 Q13546 1/20 0.34
USP30 Q70CQ3 1/20 0.34
PIK3CD O00329 1/20 0.34
GRAMD1A Q96CP6 1/20 0.33
NTMT1 Q9BV86 1/20 0.33
PIK3CA P42336 1/20 0.33
PIK3CB P42338 1/20 0.33
PIK3CG P48736 1/20 0.33
BRD4 O60885 1/20 0.33
CREBBP Q92793 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9903640 0.84 RIPK1 (0.38) RIPK1PIK3CAPIK3CBPIK3CG
SCHEMBL9901781 0.81 MKNK1 (0.42) GPR119USP2SMN1; SMN2ESR2SCD5
SCHEMBL3280283 0.80 MAPK1 (0.44) GPR119USP2SMN1; SMN2ESR2MAPT
SCHEMBL9903677 0.79 USP2 (0.44) USP2SMN1; SMN2ESR2ADORA1KDM4E
SCHEMBL3276194 0.79 GPR119 (0.42) GPR119USP2SMN1; SMN2ESR2NR1H2
SCHEMBL9902475 0.76 USP2 (0.42) USP2SMN1; SMN2ESR2ADORA1KDM4E
SCHEMBL9902986 0.75 USP2 (0.41) GPR119USP2SMN1; SMN2ESR2ADORA1
SCHEMBL9903878 0.75 USP2 (0.41) USP2SMN1; SMN2ESR2ADORA1KDM4E
Hydrochloric Acid SCHEMBL11893474 0.74 USP2 (0.40) GPR119USP2SMN1; SMN2ESR2ADORA1
SCHEMBL9903300 0.73 USP2 (0.39) USP2SMN1; SMN2ESR2ADORA1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8916549-B2 Thienooxazepine derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-12-23 US disclosed
EP-2463290-B1 THIENOOXAZEPINE DERIVATIVE TAKEDA PHARMACEUTICAL (JP) 2014-03-05 EP disclosed
US-20120196848-A1 THIENOOXAZEPINE DERIVATIVE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-02 US disclosed
EP-2463290-A1 THIENOOXAZEPINE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2012-06-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120196848-A1 THIENOOXAZEPINE DERIVATIVE HTR2C, HTR2B, HTR2A GPR119 283/4885USP2 3930/4885SMN1; SMN2 3302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.